-
Arvinas Inc. NASDAQ:ARVN Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Location: | Website: arvinas.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
621.1M
Cash
1.122B
Avg Qtr Burn
-64.58M
Short % of Float
15.40%
Insider Ownership
7.22%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vepdegestrant (ARV-471) (oral ER-targeting PROTAC® protein degrader) + palbociclib Details Breast cancer, Cancer, Solid tumor/s | Phase 3 Data readout | |
Vepdegestrant (ARV-471)(oral ER-targeting PROTAC® protein degrader) Details Breast cancer, Cancer, Solid tumor/s Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s | Phase 2 Data readout | |
Vepdegestrant (ARV-471)+CDK7 inhibitor (samuraciclib) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
Bavdegalutamide (ARV-110) (PROTAC protein degrader) +/- abiraterone Details Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s | Phase 1/2 Update | |
ARV-766 +/- abiraterone Details Solid tumor/s, Castration-resistant prostate cancer, Prostate cancer, Cancer | Phase 1/2 Update | |
Vepdegestrant (ARV-471)+CDK4 inhibitor Details Solid tumor/s, Cancer, Breast cancer | Phase 1/2 Update | |
ARV-393 [PROTAC BCL6 degrader] Details Cancer, B-cell lymphoma, Blood cancer | Phase 1 Data readout | |
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s | Phase 1 Data readout | |
ARV-102 (PROTAC® LRRK2 degrader) Details Neurodegenerative disease | Phase 1 Data readout |